Flupirtine
Flupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe. It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia
General
Type : Pro-Drug, Drug, Not AlphaBeta Hydrolase target, Carbamate
Chemical_Nomenclature : ethyl N-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate
Canonical SMILES : CCOC(=O)NC1=C(N=C(C=C1)NCC2=CC=C(C=C2)F)N
InChI : InChI=1S\/C15H17FN4O2\/c1-2-22-15(21)19-12-7-8-13(20-14(12)17)18-9-10-3-5-11(16)6-4-10\/h3-8H,2,9H2,1H3,(H,19,21)(H3,17,18,20)
InChIKey : JUUFBMODXQKSTD-UHFFFAOYSA-N
Other name(s) : D 9998 || MOH3ET196H
MW : 304.32
Formula : C15H17FN4O2
CAS_number : 56995-20-1
PubChem : 53276
UniChem : JUUFBMODXQKSTD-UHFFFAOYSA-N
Target
Structures : No structure
Families : Carb_B_Chordata
References (1)
| Title : In vitro approach to elucidate the relevance of carboxylesterase 2 and N-acetyltransferase 2 to flupirtine-induced liver injury - Konishi_2018_Biochem.Pharmacol_155_242 |
| Author(s) : Konishi K , Fukami T , Ogiso T , Nakajima M |
| Ref : Biochemical Pharmacology , 155 :242 , 2018 |
| Abstract : |
| PubMedSearch : Konishi_2018_Biochem.Pharmacol_155_242 |
| PubMedID: 30028988 |